Neonc Technologies Holdings, Inc.

NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries

NeOnc Technologies outlined plans for an international trial of NEO100 targeting approximately 500 patients across 30 hospitals in three countries, discussed on a Fox Business segment. NEO100 uses intranasal delivery to bypass the blood-brain barrier, with patient selection focused on IDH-mutation characteristics; prior clinical updates reported radiographic remission in six of 25 patients (24%). The expansion figures describe planned participation rather than completed enrollment, and the release is a paid 24/7 Market News editorial rather than a company announcement of a trial start.

•6d ago

NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue

A paid 24/7 Market News editorial highlights NeOnc's technical breakout above $3 and a reported 45.1% rise in short interest to 757,739 shares. The piece recaps an October 21 MOU with the Department of Health-Abu Dhabi and two children receiving investigational NEO100 through a Compassionate Care program. Published analyst targets cited average $17, but the release is compensated promotion by NTHI and should be treated as low-signal marketing rather than issuer disclosure.

•9d ago

NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration

NeOnc Technologies signed a non-binding Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on CNS oncology research, specialist training, real-world evidence, and assessment of clinical trial opportunities in the Emirate. The MoU builds on June 2026 DoH IND clearances for NEO100 and NEO212 and on NeOnc's Compassionate Care program, through which two children in Abu Dhabi are receiving investigational NEO100, with a third expected from India this week. The company is working to open a Phase 1 NEO100 study in Abu Dhabi. The parties will also explore a potential regional presence, including manufacturing, supply or distribution activities, and positioning Abu Dhabi as a platform for future development activities — all subject to separate definitive agreements and regulatory approvals. The MoU is explicitly non-binding, runs two years, and commits neither party.

•11d ago

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NeOnc reported early clinical improvement in the first child treated with investigational intranasal NEO100 under its Compassionate Care program in Abu Dhabi. According to treating physicians, the critically ill three-year-old with an aggressive brain tumor is now breathing without ventilator support and beginning to move his legs after treatment began. The company cautions the single-patient observation does not establish causation, safety, or efficacy; NEO100 remains investigational, with a pediatric Phase 1/1b pathway pending protocol review alongside adult Phase 1-2 studies.

•16d ago

NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development

NeOnc Technologies appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its board effective October 9, 2026, succeeding Dr. Steven L. Giannotta, who remains on the Scientific Advisory Board. The company disclosed that Abu Dhabi's health regulator granted IND authorization supporting NEO212 development in the UAE, and an End-of-Phase 1 Type B FDA meeting on NEO212 is set for November 17, 2026. NeOnc also recapped prior milestones, including NEO100 Phase 2a results with 48.9% six-month progression-free survival and the redemption of its Series A convertible preferred stock eliminating potential dilution. This is a paid 24/7 Market News promotional editorial, not an issuer disclosure of new results.

•18d ago

NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

A paid 24/7 Market News editorial highlights NeOnc Technologies' Phase 2a study of intranasal NEO100 in recurrent Grade III/IV IDH1-mutant glioma, reporting median overall survival of 26.09 months in 24 patients measured from first post-recurrence treatment dose. The article stresses the data are an uncontrolled survival signal, not randomized proof, with PFS reaching significance only under RANO 2.0 criteria; NeOnc plans to discuss a registrational pathway with the FDA. A separate confirmed FDA End-of-Phase 1 meeting for the NEO212 program is set for November 17, 2026. The release is a compensated promotional communication and recaps previously disclosed data, so it should be treated as low-signal marketing rather than new issuer news.

•25d ago

NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt

NeOnc Technologies enters a fall regulatory window with an anticipated October FDA Type B end-of-Phase 2 discussion for NEO100 and a confirmed in-person FDA end-of-Phase 1 meeting for NEO212 on November 17, 2026. The backdrop is NEO100 Phase 2a data from August: 48.9% six-month progression-free survival versus a 20% prespecified historical benchmark, and 26.09-month median overall survival in a 24-patient open-label study of recurrent IDH1-mutant high-grade glioma. Note this is a paid 24/7 Market News editorial compensated by NTHI, not a company disclosure; analyst Buy initiations from Roth Capital, Alliance Global Partners, Maxim Group and BTIG are recapped but no new material information is announced.

•26d ago

NeOnc’s Powerful Brain Cancer Pipeline Advances

NeOnc Technologies has an FDA End-of-Phase 1 Type B meeting scheduled for November 17, 2026, to discuss NEO212's proposed Phase 2 design, endpoints, dose selection and potential accelerated-approval strategy for aggressive CNS cancers. NEO212 completed Phase 1 with a recommended Phase 2 dose of 610 mg, supported by individual-patient signals (including ~60% tumor reduction in a recurrent glioblastoma patient) that are not controlled efficacy evidence. Lead program NEO100 previously beat its prespecified benchmark with 48.9% six-month progression-free survival versus 20% in recurrent IDH1-mutant glioma. The company recently raised $15 million at $4.20 per share, redeemed all Series A preferred shares for $6 million, and reported roughly $629,000 in insider open-market purchases. Note this is paid third-party editorial coverage from InvestorsTape.com, not an issuer disclosure; the November meeting outcome is the real catalyst.

•1mo ago

Powerful NeOnc Brain Cancer Pipeline Advances

NeOnc Technologies holds an in-person FDA End-of-Phase 1 Type B meeting for NEO212 on November 17, 2026, seeking feedback on patient population, trial design, endpoints, dosing and potential accelerated-approval strategy. Phase 1 established a recommended Phase 2 dose of 610 mg (MTD 810 mg), with early anecdotes including a glioblastoma patient with roughly 60% tumor reduction and 21 months of disease control — individual observations, not efficacy evidence. The pipeline story extends to NEO100, whose Phase 2a topline showed 48.9% six-month PFS versus a 20% benchmark and 26.09-month median overall survival; Roth Capital initiated coverage with a $20 target. Note this article is a paid editorial: 24/7 Market News is compensated by NTHI, and the company recently raised capital at $4.20 per share with warrants while insiders bought in the open market.

•1mo ago

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

NeOnc Technologies will meet with the FDA on November 17, 2026 at the agency's White Oak campus for an in-person End-of-Phase 1 Type B meeting on NEO212 in CNS cancers. The company will seek feedback on patient population, trial design, endpoints, dose selection and evidence needed for a marketing application, including whether a design could support an accelerated approval pathway. The meeting's scheduling does not imply FDA agreement. Phase 1 dose escalation was completed with 610 mg selected as the recommended Phase 2 dose after a dose-limiting toxicity at 810 mg. Notable Phase 1 activity included a ~60% tumor reduction with 21 months of disease control in a recurrent GBM patient and ~16 months of stable disease in a brain-metastases patient, though individual outcomes do not establish efficacy.

•1mo ago

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

Roth Capital's Jonathan Aschoff initiated coverage of NeOnc Technologies (NTHI), reportedly expecting an FDA Type B End-of-Phase 2 meeting for NEO100 in October and potential pivotal-trial starts before end-2026. The release recaps August Phase 2a topline data in recurrent IDH1-mutant high-grade glioma: six-month progression-free survival of 48.9% versus a 20% prespecified benchmark and median overall survival of 26.09 months, with a registrational path to be discussed with FDA. NEO212 has an established Phase 2 dose of 610 mg, and the company raised $15 million in September via a registered direct offering at $4.20 per share with $4.20 warrants to fund the next development phase. Important caveat: this is a paid 24/7 Market News editorial compensated by NTHI, and the analyst timelines are expectations, not FDA commitments.

•1mo ago

NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

NeOnc Technologies reported Phase 2a data for NEO100, an intranasal brain-delivery drug for recurrent IDH1-mutant high-grade glioma, with six-month progression-free survival of 48.9% versus a prespecified 20% benchmark (p=0.0047). Median overall survival was 26.09 months, five of 24 patients remained on treatment, and no major toxicities were reported in the small cohort. The company plans a Type B FDA meeting to discuss a registrational pathway, but the signal comes from a single-arm 24-patient study and Novocure's failed Phase 3 TRIDENT trial underscores translation risk. Note this article is a paid 24/7 Market News promotional editorial, not an issuer disclosure.

•1mo ago

NeOnc Charting New Nasal Route to Treating Brain Cancer

NeOnc Technologies Holdings (NASDAQ: NTHI) is touting NEO100, an intranasal formulation of purified perillyl alcohol, after its Phase 2a NEO100-01 study in recurrent or progressive Grade III/IV IDH1-mutant glioma reported six-month progression-free survival of 48.9% versus a 20% standard-of-care benchmark, with a one-sided p-value of 0.0047. The 24-patient open-label study reported median overall survival of 26.09 months and 86.7% overall survival at six months, but the six-month PFS estimate carried a wide confidence interval of 26.3% to 68.1%, and only five of 24 patients remained on treatment at the readout. NeOnc says it intends to request a Type B meeting with the FDA to discuss a potential registrational path for NEO100 in recurrent IDH1-mutant high-grade glioma; the at-home regimen is dosed intranasally four times daily in 28-day cycles, with no major toxicities reported. Importantly, this release is a paid editorial from 24/7 Market News, which discloses it is compensated by NTHI, and it recaps topline data first reported on August 12, 2026 rather than containing new company disclosure.

•1mo ago

NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

NeOnc Technologies redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing zero common shares in the process. The redemption was funded by a $15 million registered direct offering announced days earlier and closes the door on a conversion feature that would have allowed holders to convert at 80% of the lowest closing price over the prior five trading days (with a $1 floor) once the four-month redemption window lapsed. On the pipeline, NEO100 recently posted topline Phase 2a data in recurrent IDH1-mutant high-grade glioma — six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months — while NEO212 completed Phase 1 dose escalation with a 610 mg recommended Phase 2 dose and UAE IND authorization. Note the sourcing: this is a paid editorial from 24/7 Market News, which is compensated by NTHI, and the clinical data and offering were previously disclosed — only the redemption itself is new.

•1mo ago

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

NeOnc Technologies redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock at an aggregate stated value of $6.0 million, and no shares of the preferred remain outstanding. The redemption was funded from the $15 million registered direct offering announced September 9, 2026; the preferred had been issued only three months earlier, in June 2026, for gross proceeds of $5.0 million. Had it not been redeemed, the stated value would have stepped up by $166.67 per share and holders could have converted at 80% of the lowest closing price over the prior five trading days, subject to a $1.00 floor — a discounted-conversion overhang now eliminated without issuing common shares. Executive Chairman and CEO Amir Heshmatpour framed the move as simplifying the capital structure while Phase 2 CNS candidates NEO100 and NEO212 advance under FDA Fast-Track and IND status.

•1mo ago

NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

Two NeOnc Technologies Holdings (NASDAQ: NTHI) executives have bought approximately $629,000 of stock in the open market with personal funds since the company announced its Phase 2a results on August 12. CEO and Executive Chairman Amir F. Heshmatpour purchased 35,000 shares on September 15 for roughly $115,400 at about $3.30 per share, bringing his post-results buying to 111,000 shares for approximately $418,700 at an average of about $3.77; Founder and Chief Medical Officer Thomas C. Chen bought 49,016 shares for approximately $210,000. The buying follows the NEO100-01 Phase 2a study meeting its primary endpoint in recurrent brain cancer, with six-month progression-free survival of 48.9% versus a pre-specified 20% standard-of-care benchmark (p-value 0.0047) and median overall survival of 26.09 months; the second program, NEO212, has completed Phase 1 dose escalation with a recommended Phase 2 dose established. Readers should note this is a paid editorial: 24/7 Market News discloses it is compensated by NTHI for ongoing coverage, the company recently announced a $15 million registered direct offering, and the forward-looking statements section references the company's ability to continue as a going concern.

•1mo ago

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

NeOnc executives have bought approximately $629,000 of NTHI stock in the open market since the company reported positive NEO100 Phase 2a results on August 12, 2026. CEO Amir Heshmatpour added 35,000 shares on September 15 for about $115,400 at roughly $3.30 per share, bringing his total since the data to 111,000 shares for about $418,700; co-founder and CSO Thomas Chen bought 49,016 shares for about $210,000, all with personal funds. The buying followed a $15 million registered direct offering announced September 9, and the Phase 2a study met its primary endpoint with 48.9% six-month progression-free survival versus a 20% standard-of-care benchmark (p = 0.0047) and median overall survival of 26.09 months. Heshmatpour says he has now invested more than $1.5 million of personal funds over the past year — a conviction signal worth noting, though the underlying study was a single-arm, 24-patient open-label trial with the company itself cautioning results may not replicate.

•1mo ago

Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus

NeOnc CEO Amir Heshmatpour bought another 37,000 NTHI shares on September 11 at a weighted-average price of $3.6654, roughly $135,620 of additional investment, per a September 14 Form 4. The piece recaps the $15 million financing announced September 9, priced at $4.20 per share plus five-year warrants for another 3.57 million shares at the same $4.20 exercise price, with proceeds earmarked for working capital, general corporate purposes, and redemption of Series A convertible preferred stock. It also restates the August 12 NEO100 Phase 2a topline: in 24 patients with recurrent or progressive high-grade IDH1-mutant glioma, six-month progression-free survival was 48.9% against a 20% historical benchmark, median overall survival was 26.09 months, and the company intends to request a Type B FDA meeting; NEO212 completed Phase 1 dose escalation with 610 mg selected as the recommended Phase 2 dose. Treat with caution: the publisher discloses it was compensated for coverage of NeOnc, and the NEO100 data come from a small, single-arm, open-label study without a randomized control group.

•1mo ago

Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test

NeOnc Technologies CEO, President and director Amir F. Heshmatpour bought another 37,000 NTHI shares at $3.6654 apiece — roughly $136,000 — shortly after the company announced a $15 million registered direct offering at $4.20 per share. Founder and Chief Scientific Officer Thomas C. Chen also made substantial purchases in August, continuing a pattern of repeated insider buying highlighted in the release. On the clinical side, NEO100 posted a 48.9% six-month progression-free survival rate in recurrent IDH1-mutant high-grade glioma versus a pre-specified 20% benchmark, with 26.09-month median overall survival, and NeOnc plans to request a Type B FDA meeting on a potential registrational path. This is a paid editorial from 24/7 Market News, which is compensated by NTHI; the clinical results are a recap of previously reported topline Phase 2a data from a small, open-label, single-arm study, not new disclosure.

•1mo ago

NeOnc' Phase 2 Data Could Put Cancer on the Ropes

NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline results on August 12 from its NEO100-01 Phase 2a study in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Six-month progression-free survival was 48.9% versus the 20% prespecified benchmark (p-value 0.0047), median overall survival was 26.09 months, and 86.7% of patients were alive at six months. The next catalyst is a planned Type B meeting with the FDA to discuss a potential registrational pathway for NEO100, an intranasal formulation of purified perillyl alcohol designed for nose-to-brain delivery in aggressive gliomas. CEO Amir Heshmatpour called the results an important milestone and said the priority is aligning with the FDA on the most efficient path to a registrational study. The broader pipeline includes UAE IND authorizations for NEO100 covering three adult programs from Phase 1 through Phase 2 plus pediatric development, and for NEO212, an oral perillyl alcohol-temozolomide conjugate with a recommended Phase 2 dose of 610 mg after Phase 1 dose escalation. Insiders have added support: director Thomas Chen bought 33,787 shares at a weighted average $3.8477 on August 14 and 2,472 shares at $4.0445 on August 17, with additional August purchases by CEO Heshmatpour. This article is a paid 24/7 Market News editorial, and the firm discloses it is compensated by NTHI for coverage and market outreach, so the promotional framing warrants skepticism and verification against the company's own filings.

•1mo ago

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

NeOnc reported positive Phase 2a data for NEO100 in recurrent glioma, showing 48.9% six-month progression-free survival against a 20% benchmark with a p-value of 0.0047. Median overall survival was 26.09 months, and the company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway. Recent insider activity includes purchases by CEO Amir Heshmatpour and Director Thomas Chen, who bought over 36,000 shares combined in mid-August.

•2mo ago

NeOnc’s Clinical Story Is Now the Main Event

NeOnc reported positive Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant glioma, achieving a primary endpoint of 48.9% six-month progression-free survival versus a 20% benchmark with a p-value of 0.0047. Management plans to request a Type B meeting with the FDA to discuss a potential registrational pathway for the intranasal therapy, which aims to address the challenge of delivering therapeutics across the blood-brain barrier. Insider sentiment appears strong, with CEO Amir Heshmatpour and Director Thomas Chen increasing their open-market holdings following the data readout.

•2mo ago

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t

NeOnc Technologies CEO Amir Heshmatpour purchased 15,000 shares on the open market between August 14 and August 17 at a weighted average price of $3.91, totaling approximately $58,600. The buying follows positive Phase 2a data for NEO100 in recurrent IDH1-mutant high-grade glioma, which reported a 48.9% six-month progression-free survival rate versus a 20% historical benchmark with a p-value of 0.0047. NeOnc intends to seek a Type B FDA meeting to discuss a potential registrational pathway, and the company also noted that its second asset, NEO212, has established a recommended Phase 2 dose of 610 mg.

•2mo ago

NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

NeOnc Technologies reported Phase 2a data for NEO100 in recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-free survival rate compared to a 20% historical benchmark with a p-value of 0.0047. Median overall survival was approximately 26.1 months, with 24-month overall survival at 54.1%, representing a substantial extension over historical expectations. The company holds a $75 million ATM facility and noted that these clinical results could strengthen its negotiating position for financing future development, with Q2 R&D expenses rising to $2.6 million from $0.7 million a year prior.

•2mo ago

New to The Street Airs This Weekend Across Bloomberg Television U.S., Latin America and MENA

Big Sky Industrial Corp. will have its corporate commercials air this weekend on Bloomberg Television across the U.S., Latin America and the MENA region as part of the New to The Street sponsored programming block. The media platform is expanding its international footprint with the new "Nuevo a la Calle" brand in Latin America and plans to enter the Southeast Asia market in Q4 2026, supported by a digital ecosystem of over 6.2 million subscribers. The broadcast features interviews and updates from Envoy Medical, Sagtec Global, RHINO Bitcoin and Virtuix, alongside commercials for several other publicly traded companies.

•2mo ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners issued a coverage update highlighting positive Phase 2a data for NeOnc Technologies' lead asset NEO100, which met its primary endpoint with a six-month PFS of 48.9% versus a 20% benchmark (p=0.0047). The study reported median overall survival of 26.09 months with no major toxicities, paving the way for the company to request a Type B FDA meeting to discuss a registrational pathway. Additionally, the company's second asset NEO212 achieved Phase 2 CMC clearance with potential for an accelerated approval pathway, while R&D expenses rose to $2.6 million from $0.7 million year-over-year.

•2mo ago

The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

A paid editorial recaps NeOnc's Phase 2a data for NEO100, reporting a 48.9% six-month progression-free survival rate against a 20% historical benchmark with statistical significance (p=0.0047). Median overall survival reached 26.09 months, while the company detailed a portfolio of 179 biotech-related patents covering intranasal delivery and its drug candidates. NeOnc plans to request a Type B FDA meeting to align on a registrational path, with NEO100 holding Orphan Drug, Fast Track and Rare Pediatric Disease designations.

•2mo ago

Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc Technologies reported positive Phase 2a data for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, with six-month progression-free survival reaching 48.9% versus a 20% benchmark (p=0.0047). Median overall survival was 26.09 months, and the study reported no major toxicities across the 24-patient cohort, which remains open-label. Based on these results, NeOnc plans to request a Type B meeting with the FDA to discuss a potential registrational development path for the therapy.

•2mo ago

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma showed 48.9% six-month progression-free survival, nearly 2.5x the 20% historical benchmark (p=0.0047). Median overall survival reached approximately 26 months with no major toxicities reported in the 24-patient open-label study. NeOnc plans to meet with the FDA to discuss a path toward a larger registrational study following these positive signals.

•2mo ago

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies reported positive topline results from the Phase 2a portion of the NEO100-01 study, meeting its primary endpoint with a six-month progression-free survival rate of 48.9% compared to a 20% historical benchmark. Median overall survival was 26.09 months, and the intranasal therapy showed no major toxicities across the cohort of 24 patients with recurrent IDH1-mutant high-grade glioma. The company intends to request a Type B meeting with the FDA to align on a registrational development path for NEO100 in a setting with currently no approved targeted therapies.

•2mo ago

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

NeOnc Technologies is scheduled to present topline Phase 2a data for NEO100 on August 12, evaluating the treatment in patients with recurrent IDH1-mutant high-grade glioma. CEO Amir Heshmatpour has invested over $500,000 in open-market purchases, with total insider buying approaching $1 million over the past year. NEO100 currently holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA.

•2mo ago

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

NeOnc Technologies appointed Nasim Shomali to its Board of Directors, effective July 1, 2026, adding expertise in corporate strategy and financial planning to the governance team. Ms. Shomali brings over a decade of experience advising Fortune-100 companies at Accenture and private equity diligence at Maybrook Capital Partners, supported by a background in biomedical engineering and finance. CEO Amir Heshmatpour emphasized that her judgment and disciplined approach to capital allocation will strengthen the Board as the company approaches key clinical and regulatory milestones.

•3mo ago

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies received written feedback from the FDA regarding the CMC development program for NEO212, enabling the company to cancel a scheduled Type B meeting as the responses were deemed sufficient. The FDA stated the proposed CMC approach appears reasonable and indicated that drug-product development can proceed in parallel with the planned late-stage clinical program, pending appropriate data. To support the transition from capsule to tablet formulation, the company must complete an in vivo relative bioavailability study and finalize tablet manufacturing processes before the confirmatory clinical phase.

•3mo ago

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

NeOnc Technologies received a second IND authorization from the UAE Department of Health for its lead candidate NEO100, covering adult Phase 1 through Phase 2 protocols and a pediatric pathway. The report highlights significant insider confidence, noting that CEO Amir Heshmatpur invested over $500,000 in open-market purchases recently, with total insider buying approaching $1 million over the past year. This communication is a paid editorial distributed by 24/7 Market News, which disclosed compensation from NTHI for coverage and investor relations services.

•4mo ago

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies received UAE IND approval for lead candidate NEO100, covering Phase 1 through Phase 2 adult protocols as well as pediatric studies. This authorization complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and extends the company's footprint beyond its NEO212 program. NeOnc confirmed it expects to report top-line data from the fully enrolled NEO100-01 Phase 2a trial by the end of July 2026, with potential implications for Breakthrough Therapy designation.

•4mo ago

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

NeOnc Technologies received Investigational New Drug authorization from the Department of Health - Abu Dhabi for its lead candidate NEO212, targeting aggressive brain cancers. The company has completed its Phase 1 dose-escalation study and identified 610 mg as the recommended Phase 2 dose, with plans for a Type B meeting with the FDA. While the Abu Dhabi clearance provides an additional clinical development pathway, the therapy remains in development with significant regulatory hurdles ahead.

•4mo ago

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

NeOnc Technologies secured IND authorization from the Department of Health – Abu Dhabi for NEO212, marking its first international regulatory clearance and enabling clinical development outside the U.S. The company completed a Phase 1 dose-escalation study establishing 610 mg as the recommended Phase 2 dose, while its NEO100 program finished Phase 2a enrollment with data expected later this year. Management confidence is signaled by over $500,000 in recent insider purchases by CEO Amir Heshmatpour, supported by financial flexibility including a $75 million ATM facility.

•4mo ago

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

NeOnc received Investigational New Drug authorization from the Abu Dhabi Department of Health for NEO212, establishing 610 mg as the recommended Phase 2 dose following the completion of a Phase 1 dose-escalation study. The company's NEO100 program has achieved full enrollment in a Phase 2a study for recurrent IDH1-mutant high-grade glioma, with prior data indicating approximately 24% tumor remission in recurrent glioblastoma patients. Chairman and CEO Amir Heshmatpour has purchased over $500,000 in shares recently, bringing total insider buying to nearly $1 million in the past year, while the company maintains access to a $75 million ATM facility and a $10 million credit line.

•4mo ago

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

NeOnc Technologies Holdings, Inc. announced that the Abu Dhabi Department of Health has granted Investigational New Drug status for NEO212, its oral conjugate therapy for aggressive brain tumors. This clearance follows the completion of the Phase 1 dose-escalation study, which identified 610 mg as the recommended Phase 2 dose and demonstrated early signs of clinical activity in pretreated patients. The authorization creates an international clinical pathway while the company continues discussions with the U.S. FDA regarding a potential registrational strategy for the drug.

•4mo ago

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

NeOnc reported a Q1 2026 net loss of $8.8 million, a significant improvement from the $32.3 million loss in Q1 2025, driven by reduced non-cash stock-based compensation and listing fees. Clinically, the company completed Phase 1 dose-escalation for NEO212, setting the recommended Phase 2 dose at 610 mg, and is preparing for an FDA meeting to discuss a pivotal registrational study. The Phase 2a trial for NEO100 is fully enrolled with interim data expected in August 2026. Liquidity was strengthened by a $10 million PIPE financing anchored by Cinctive Capital and a $10 million undrawn credit line. Combined with existing cash, these resources are expected to fund operations into September 2026. CEO Amir Heshmatpour also purchased over $500,000 of shares on the open market.

•5mo ago

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

CEO Amir Heshmatpour significantly increased his personal ownership by purchasing over $500,000 of NeOnc shares in recent weeks, bringing his total investment over the past year to nearly $1 million. The buying aligns with upcoming clinical milestones, specifically the interim analysis for the fully enrolled Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma expected later this year. Additionally, the company reported the completion of NEO212's Phase 1 dose escalation and the establishment of a recommended Phase 2 dose.

•5mo ago